Emami Reports Strong Q3FY26 Performance with 11% Revenue Growth and Margin Expansion

2 min read     Updated on 04 Feb 2026, 02:47 PM
scanx
Reviewed by
Ashish TScanX News Team
Overview

Emami Limited delivered exceptional Q3FY26 performance with consolidated net sales growing 11% to ₹1,147 crore and net profit increasing 15% to ₹319 crore. The company achieved significant margin expansion with EBITDA margins improving 110 basis points to 33.4%, supported by strong domestic volume growth of 9% and healthy performance across all major brands including BoroPlus (+16%), Kesh King (+10%), and Pain Management (+8%). The Board declared a second interim dividend of ₹6 per share.

31742251

*this image is generated using AI for illustrative purposes only.

Emami Limited has delivered exceptional financial performance in Q3FY26, reporting consolidated net sales of ₹1,147 crore compared to ₹1,036 crore in the corresponding quarter of the previous year. The consumer goods company achieved consolidated net profit of ₹319 crore, marking a significant 15% increase from ₹279 crore in the same period last year.

Outstanding Financial Performance

The company's quarterly results demonstrate robust growth across all key financial metrics. Net sales growth of 11% year-on-year, combined with the 15% increase in net profit, showcases Emami's ability to drive both top-line and bottom-line expansion. The company reported EBITDA of ₹384 crore, representing a substantial 13% increase from ₹339 crore in the corresponding quarter of the previous year.

Financial Metric: Q3FY26 Q3FY25 Growth (%)
Net Sales: ₹1,147 crore ₹1,036 crore +11%
Revenue from Operations: ₹1,152 crore ₹1,050 crore +10%
Net Profit: ₹319 crore ₹279 crore +15%
EBITDA: ₹384 crore ₹339 crore +13%
EBITDA Margin: 33.4% 32.3% +110 bps
PBT before Exceptionals: ₹355 crore ₹301 crore +18%

Exceptional Margin Expansion

Emami's EBITDA margin improved significantly to 33.4% in Q3FY26, compared to 32.3% in the same period last year, reflecting enhanced operational efficiency and superior cost management. This margin expansion of 110 basis points demonstrates the company's ability to optimize its cost structure while maintaining strong growth momentum across its business operations. Gross margins also expanded to 70.6%, an improvement of 30 basis points.

Strong Domestic and International Performance

The domestic business delivered growth of 11%, driven by robust volume growth of 9%. All major brands registered healthy performance during the quarter, with BoroPlus Range leading growth at 16%, followed by Kesh King Range at 10%, Pain Management Range at 8%, and Healthcare Range at 7%. The international business recorded sales growth of 9%, contributing 15% to overall sales, with strong performance across SAARC, MENA, and CIS regions.

Brand Performance: Q3FY26 Growth
BoroPlus Range: +16%
Kesh King Range: +10%
Pain Management Range: +8%
Healthcare Range: +7%
Male Grooming Range: +4%
7 Oils in One: +41%

Strategic Innovation and Product Launches

During the quarter, Emami launched several new products including Kesh King Gold Advanced Hair Growth Serum, BoroPlus Deeply Moisturising Lip Balm, Zandu Apple Cider Vinegar Effervescent Tablets, and Zandu Good Gut Constipation Relief Tablets. The Man Company introduced Vitamin C and Anti Acne Facewash, Moisturizing Gel Cream, and Anti Dandruff Shampoo, further strengthening its premium male grooming segment.

Interim Dividend Declaration

The Board of Directors declared a second interim dividend of 600%, amounting to ₹6 per share for FY26. With this declaration, the total dividend for the nine months ended FY26 stands at ₹10 per share, demonstrating the company's confidence in its financial strength and commitment to rewarding shareholders.

Source: Emami Limited Investor Presentation Q3FY26

Historical Stock Returns for Emami

1 Day5 Days1 Month6 Months1 Year5 Years
+1.28%-1.35%-6.37%-21.00%-20.36%+0.65%

Emami Limited Schedules Board Meeting and Investor Conference Call on February 4, 2026

2 min read     Updated on 07 Jan 2026, 04:54 PM
scanx
Reviewed by
Radhika SScanX News Team
Overview

Emami Limited will hold its board meeting on February 4, 2026, to review Q3FY26 unaudited financial results and consider declaring a second interim dividend for FY2025-26. The company has also scheduled an investor conference call at 4:00 PM IST on the same day, featuring key management personnel including Vice Chairman Mr. Mohan Goenka and other senior executives to discuss business strategy and outlook post results declaration.

29330670

*this image is generated using AI for illustrative purposes only.

Emami Limited has announced that its Board of Directors will convene on February 4, 2026, to deliberate on the company's third-quarter financial performance and potential dividend distribution. Additionally, the company will host an investor conference call on the same day to discuss business strategy and outlook following the results announcement.

Board Meeting Agenda

The board meeting will focus on two primary agenda items that are crucial for shareholders and market participants:

Agenda Item: Details
Financial Results: Unaudited standalone and consolidated results for Q3FY26
Quarter Period: October 1, 2025 to December 31, 2025
Dividend Consideration: Second interim dividend for FY2025-26
Meeting Date: February 4, 2026 (Wednesday)

The company will review its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. Additionally, the board will deliberate on the declaration of a second interim dividend for the financial year 2025-26, though the final decision remains subject to board approval.

Investor Conference Call Details

Following the board meeting, Emami Limited will conduct a conference call with analysts and investors to discuss the quarterly results and business outlook:

Parameter: Details
Date & Time: Wednesday, February 4, 2026 at 4:00 PM IST
Purpose: Discuss business strategy and outlook post Q3FY26 results
India Access Numbers: +91 22 6280 1259 / +91 22 7115 8160
International Access: USA: 18667462133, UK: 08081011573
Additional Markets: Singapore: 8001012045, Hong Kong: 800964448

Management Participation

The conference call will feature key management personnel who will provide insights into the company's performance and strategic direction:

Position: Name
Wholetime Director & Vice Chairman: Mr. Mohan Goenka
CEO (International Business): Mr. Vivek Dhir
President (Healthcare): Mr. Gul Raj Bhatia
President (Sales): Mr. Manish Gupta
Chief Growth Officer: Mr. Giriraj Bagri
President (Finance & IR): Mr. Rajesh Sharma

Trading Window Restrictions

Emami Limited has implemented trading window restrictions in accordance with insider trading regulations:

Parameter: Timeline
Trading Window Closure Start: January 1, 2026 (Thursday)
Trading Window Closure End: February 6, 2026 (Friday)
Total Closure Period: 37 days
Regulatory Compliance: SEBI insider trading norms

The extended closure period ensures compliance with regulatory requirements surrounding the announcement of quarterly financial results and potential dividend declarations.

Regulatory Compliance

Both announcements were made pursuant to SEBI regulations - the board meeting under Regulation 29 and the conference call under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These regulations mandate listed companies to inform stock exchanges about significant corporate developments.

Emami Limited's Company Secretary and Compliance Officer, Ravi Varma, signed the official communications to both NSE and BSE on January 7, 2026. The company maintains transparency with market participants by providing advance notice of significant corporate developments that may impact investor decisions.

Historical Stock Returns for Emami

1 Day5 Days1 Month6 Months1 Year5 Years
+1.28%-1.35%-6.37%-21.00%-20.36%+0.65%

More News on Emami

1 Year Returns:-20.36%